Glucagon like Peptide 1 Receptor Agonist Market Report 2024 (Global Edition)

Global Glucagon like Peptide 1 Receptor Agonist Market Report 2024 Market Size Split by Drug Class (Exenatide, Liraglutide, Dulaglutide, Lixisenatide, Others), by Route of Administration (Parenteral, ...

Glucagon like Peptide 1 Receptor Agonist Market Report Description

We have various report editions of Glucagon like Peptide 1 Receptor Agonist Market, hence please contact our sales team and author directly to obtain/purchase a desired Edition eg, Global Edition, Regional Edition, Country Specific Report Edition, Company Profiles, Forecast Edition, etc. Request for your Free Sample PDF/Online Access.

Glucagon like Peptide 1 Receptor Agonist Market Insights Video

Competitive Landscape of the Glucagon like Peptide 1 Receptor Agonist Market

The market for Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) is competitive due to several major competitors, continuous R&D, strategic alliances, and market tactics. Businesses emphasize distinguishing their goods based on administration methods (e.g., injectable vs. oral), convenience of dosing (e.g., once-weekly vs. daily), and extra benefits (e.g., cardiovascular results). Partnerships and collaborations also improve market reach and innovation in R&D, marketing, and distribution. For instance, partnerships between biotech and pharmaceutical industries spur the creation of new products.

December 2023: Topline results from the Phase 2b clinical study (NCT04707313) examining danuglipron (PF-06882961), an oral GLP-1RA candidate, in people with obesity and no history of type 2 diabetes were released by Pfizer Inc. The primary objective of the trial was achieved, indicating a statistically significant alteration in body weight from the baseline. Source: https://www.pfizer.com/news/press-release/press-release-detail/pfizer-announces-topline-phase-2b-results-oral-glp-1r.

 

Top Companies Market Share in Glucagon like Peptide 1 Receptor Agonist Industry: (In no particular order of Rank)

• Novo Nordisk A/S
• Sanofi S.A.
• Eli Lilly and Company
• AstraZeneca
• Zealand Pharma A/S
• Intarcia Therapeutics
• Inc.
• GlaxoSmithKline plc
• Amgen Inc.
• Merck & Co.
• Inc.
• Adocia
• Confidential Data
• Access The Paid Version
• Data Hidden

*List of Second Tier Companies, List of Third Tier/ Start-up Companies (Inquire with sales executive) Request Any Company Profile for Preview Purpose OR Data Validation!

If any Company(ies) of your interest has/have not been disclosed in the above list then please let us know the same so that we will check the data availability in our database and provide you the confirmation or include it in the final deliverables.

Regional Analysis of the Glucagon like Peptide 1 Receptor Agonist Market

Which Region Dominates the Glucagon like Peptide 1 Receptor Agonist Market in 2024?

According to Cognitive Market Research, North America dominated the market in 2024. It accounted for around 40% of the global revenue. The prevalence of type 2 diabetes is on the rise in North America; the Centers for Disease Control and Prevention (CDC) estimates that millions of Americans are diagnosed with the disease each year; high rates of obesity fuel demand for GLP-1 RAs because these medications aid in weight management, which is a vital component of diabetes care; and the region boasts a sophisticated healthcare system that makes it easier to diagnose and treat diabetes, including easy access to endocrinologists and diabetes specialists.

Which Region is Expanding at the Fastest CAGR?

Asia Pacific stands out as the fastest-growing region in the Glucagon like Peptide 1 Receptor Agonist market. Diabetes can be diagnosed and treated more effectively with increased access to medical facilities and investments in healthcare infrastructure. The region's emerging economies are spending more on healthcare, which encourages the use of GLP-1 RAs and other modern diabetic treatments. Additionally, the public is being educated about diabetes care through government and non-governmental organizations' awareness initiatives, which is increasing the need for efficient medications like GLP-1 RAs.

 

The current report Scope analyzes Glucagon like Peptide 1 Receptor Agonist Market on 5 major region Split (In case you wish to acquire a specific region edition (more granular data) or any country Edition data then please write us on info@cognitivemarketresearch.com

• North America (United States, Canada, Mexico)
• Europe (United Kingdom, France, Germany, Italy, Russia, Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium)
• Asia-Pacific (China, Japan, Korea, India, Australia, Philippines, Singapore, Malaysia, Thailand, Indonesia, Rest of APAC)
• South America (Brazil, Argentina, Colombia, Peru, Chile, Rest of South America)
• Middle East and Africa (Saudi Arabia, Turkey, Nigeria, UAE, Egypt, South Africa, GCC Countries, Rest of MEA)

The above graph is for illustrative purposes only.

North America Glucagon like Peptide 1 Receptor Agonist

According to Cognitive Market Research, the global Glucagon like Peptide 1 Receptor Agonist market size was estimated at USD 23514.2 Million, out of which North America held the major market of more than 40% of the global revenue with market size of USD 9405.68 million in 2024 and will grow at a compound annual growth rate (CAGR) of 8.8% from 2024 to 2031.

• According to Cognitive Market Research, the US had a major share in the Glucagon like Peptide 1 Receptor Agonist market with a market size of USD 7421.08 million in 2024 and is projected to grow at a CAGR of 8.6% during the forecast period. The nation's prevalence of diabetes.
• The Canada Glucagon like Peptide 1 Receptor Agonist market had a market share of USD 1128.68 million in 2024 and is projected to grow at a CAGR of 9.6% during the forecast period. Canada's increasing investment.
• The Mexico Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 855.92 million in 2024.

Europe Glucagon like Peptide 1 Receptor Agonist

According to Cognitive Market Research, the global Glucagon like Peptide 1 Receptor Agonist market size was estimated at USD 23514.2 Million, out of which Europe held the market of more than 30% of the global revenue with a market size of USD 7054.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 9.1% from 2024 to 2031.

• The United Kingdom Glucagon like Peptide 1 Receptor Agonist market had a market share of USD 1185.12 million in 2024 and is projected to grow at a CAGR of 9.9% during the forecast period. In the UK, Glucagon like Peptide 1 Receptor Agonist sales witness an upswing due to the nation's rising investment.
• The France Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 8.3% during the forecast period, with a market size of USD 648.99 million in 2024.
• According to Cognitive Market Research, the German Glucagon like Peptide 1 Receptor Agonist market size was valued at USD 1396.74 million in 2024 and is projected to grow at a CAGR of 9.3% during the forecast period. In Germany, Glucagon like Peptide 1 Receptor Agonist surged due to the rising drug approvals.
• The Italy Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 8.5% during the forecast period, with a market size of USD 606.67 million in 2024.
• The Russia Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 8.1% during the forecast period, with a market size of USD 1093.41 million in 2024.
• The Spain Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 8.2% during the forecast period with a market size of USD 578.45 million in 2024
• The Luxembourg Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 9.2% during the forecast period, with a market size of USD 218.68 million in 2024.
• The Portugal Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 8.9% during the forecast period, with a market size of USD 148.14 million in 2024.
• The Greece Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD 84.65 million in 2024.
• Rest of Europe's Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 7.8% during the forecast period, with a market size of USD 1093.41 million in 2024.

Asia Pacific Glucagon like Peptide 1 Receptor Agonist

According to Cognitive Market Research, the global Glucagon like Peptide 1 Receptor Agonist market size was estimated at USD 23514.2 Million, out of which Asia Pacific held the market of around 23% of the global revenue with a market size of USD 5408.27 million in 2024 and will grow at a compound annual growth rate (CAGR) of 12.6% from 2024 to 2031.

• According to Cognitive Market Research, the China Glucagon like Peptide 1 Receptor Agonist market size was valued at USD 2433.72 million in 2024 and is projected to grow at a CAGR of 12.1% during the forecast period. Glucagon like Peptide 1 Receptor Agonist surged in China due to the presence of major manufacturers.
• The Japan Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD 746.34 million in 2024.
• The India Glucagon like Peptide 1 Receptor Agonist market had a market share of USD 648.99 million in 2024 and is projected to grow at a CAGR of 14.4% during the forecast period. India's increasing pharmaceutical sector.
• The South Korean Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 11.7% during the forecast period, with a market size of USD 540.83 million in 2024.
• The Australian Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 12.3% during the forecast period, with a market size of USD 281.23 million in 2024.
• The South East Asia Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 13.6% during the forecast period, with a market size of USD 373.17 million in 2024.
• The Rest of Asia Pacific Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 12.4% during the forecast period, with a market size of USD 383.99 million in 2024.

South America Glucagon like Peptide 1 Receptor Agonist

According to Cognitive Market Research, the global Glucagon like Peptide 1 Receptor Agonist market size was estimated at USD 23514.2 Million, out of which the Latin America market has more than 5% of the global revenue with a market size of USD 1175.71 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.0% from 2024 to 2031. .

• According to Cognitive Market Research, the Brazil Glucagon like Peptide 1 Receptor Agonist market size was valued at USD 503.20 million in 2024 and is projected to grow at a CAGR of 10.6% during the forecast period. Glucagon like Peptide 1 Receptor Agonists flourished in Brazil due to the growing investment.
• Argentina's Glucagon like Peptide 1 Receptor Agonist market had a market share of USD 197.52 million in 2024 and is projected to grow at a CAGR of 10.9% during the forecast period. Argentina's rising security concerns.
• Colombia Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 104.64 million in 2024.
• Peru Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 10.2% during the forecast period, with a market size of USD 96.41 million in 2024.
• Chile Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 10.3% during the forecast period, with a market size of USD 84.65 million in 2024.
• The Rest of Latin America's Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 9.1% during the forecast period, with a market size of USD 189.29 million in 2024.

Middle East and Africa Glucagon like Peptide 1 Receptor Agonist

According to Cognitive Market Research, the global Glucagon like Peptide 1 Receptor Agonist market size was estimated at USD 23514.2 Million, out of which the Middle East and Africa held the major market of around 2% of the global revenue with a market size of USD 470.28 million in 2024 and will grow at a compound annual growth rate (CAGR) of 10.3% from 2024 to 2031..

• The GCC Countries Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 11.1% during the forecast period, with a market size of USD 201.28 million in 2024. Glucagon like Peptide 1 Receptor Agonist sales flourish due to the presence of major market players.
• The Egypt Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 10.6% during the forecast period, with a market size of USD 49.38 million in 2024.
• The South Africa Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 11.3% during the forecast period, with a market size of USD 74.30 million in 2024. Glucagon like Peptide 1 Receptor Agonist sales flourish in South Africa due to regulatory support.
• The Turkey Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 9.8% during the forecast period, with a market size of USD 40.44 million in 2024.
• The Nigeria Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 9.4% during the forecast period, with a market size of USD 49.38 million in 2024.
• The Rest of MEA Glucagon like Peptide 1 Receptor Agonist market is projected to witness growth at a CAGR of 9.3% during the forecast period, with a market size of USD 55.49 million in 2024.

Glucagon like Peptide 1 Receptor Agonist Market Analysis

Glucagon like Peptide 1 Receptor Agonist Market Drug Class Segment Analysis

According to Cognitive Market Research, Exenatide stands out as the dominant category over the projected period. Exenatide's early launch and clinical efficacy have allowed it to gain a strong foothold in the GLP-1 RA market and generate consistent revenue growth. However, more recent GLP-1 RAs with better dosages and extra advantages compete with it. Exenatide's capacity to adjust to changing market conditions, control competition, and seize opportunities for innovation and better patient outcomes will determine how well it does on the market.

Dulaglutide emerges as the fastest-growing category in the Glucagon Peptide 1 Receptor Agonist market due to its once-weekly dosage schedule and efficient glucose management, dulaglutide has experienced significant revenue growth since its debut. Due to its proven effectiveness and ease of use, trulicity has been well-received in the market.

The above Chart is for representative purposes and does not depict actual sale statistics. Access/Request the quantitative data to understand the trends and dominating segment of Glucagon like Peptide 1 Receptor Agonist Industry. Request a Free Sample PDF!

Glucagon like Peptide 1 Receptor Agonist Market Route of Administration Segment Analysis

According to Cognitive Market Research, the dominant category is Parenteral. This dominance can be attributed to the widespread use of GLP 1 agonists in the treatment of diabetic patients as well as their many advantages over alternative medication regimens, including their high efficacy. Parenteral GLP-1 receptor medications that have been licensed for use in treatment include Dulaglutide (Trulicity), Liraglutide (Victoza, Saxenda), Lixisenatide (Adlyxin), Exenatide extended-release (Bydureon base), and Exenatide (Byetta). The new parenteral drug's global approval is anticipated to propel market expansion.

The fastest-growing category in the Glucagon like Peptide 1 Receptor Agonist market is Oral. One important component of type 2 diabetes patient care is the use of oral GLP-1 Receptor Agonist. The U.S. FDA currently approves semaglutide, also known as Rybelsus, for the treatment of diabetes.

The above Graph is for representation purposes only. This chart does not depict actual Market share.

Glucagon like Peptide 1 Receptor Agonist indication Segment Analysis

Glucagon like Peptide 1 Receptor Agonist Market Industry Indication Segment Analysis

According to Cognitive Market Research, the dominant category is Diabetes. The segment expansion is attributed to the growing prevalence of diabetes 2 and the growing regulatory approvals. Furthermore, the growing product launch is another factor propelling the market growth.

The fastest-growing category in the Glucagon like Peptide 1 Receptor Agonist market is cardiovascular disease. Research into additional cardiovascular benefits and expanded indications could fuel further growth in the GLP-1 RA market. The proven cardiovascular benefits of GLP-1 RAs have made them a preferred choice for patients with type 2 diabetes who are at high risk for cardiovascular events. This has led to increased adoption and higher market growth for these medications.

• Diabetes
• Cardiovascular Disease
• Weight Management
• Others

Glucagon like Peptide 1 Receptor Agonist Distribution Channel Segment Analysis

Glucagon like Peptide 1 Receptor Agonist Market Distribution Channel Segment Analysis

According to Cognitive Market Research, the dominant category is Hospital Pharmacies. The expansion of hospital pharmacies has made it easier to integrate various healthcare services, boosted the number of inpatient visits for consultations on diabetes and obesity, and enhanced patient convenience when it comes to obtaining GLP-1 drugs. Hospitalization is a major driver of the market's growth and is influenced by several factors, including the ageing population, the prevalence of diabetes, and the availability of qualified staff. The need for prescription medications and related products rises in tandem with hospital admissions, which helps hospital pharmacies grow.

The fastest-growing category in the Glucagon like Peptide 1 Receptor Agonist market is Clinics. As clinics adopt GLP-1 RAs more widely, especially those with specialized diabetes care units, the market for these medications grows. Increased prescriptions contribute to higher revenue for pharmaceutical companies.

• Hospital Pharmacies
• Clinics
• Ambulatory Surgical Centres

Author's Detail

Anushka Gore

Research Associate at Cognitive Market Research

LinkedIn

Profile

Anushka Gore is a seasoned market researcher specializing in the dynamic landscape of the Pharmaceutical industry. With a keen analytical mind and a deep passion for healthcare advancements, she has dedicated herself unraveling the intricate market trends and consumer behaviors that shape the future of medical technologies and services.

Author's Conclusion